KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Halozyme Therapeutics (HALO) Gross Profit: 2009-2024

Historic Gross Profit for Halozyme Therapeutics (HALO) over the last 16 years, with Dec 2024 value amounting to $855.9 million.

  • Halozyme Therapeutics' Gross Profit rose 24.25% to $299.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 billion, marking a year-over-year increase of 35.12%. This contributed to the annual value of $855.9 million for FY2024, which is 34.39% up from last year.
  • As of FY2024, Halozyme Therapeutics' Gross Profit stood at $855.9 million, which was up 34.39% from $636.9 million recorded in FY2023.
  • In the past 5 years, Halozyme Therapeutics' Gross Profit ranged from a high of $855.9 million in FY2024 and a low of $224.2 million during FY2020.
  • Moreover, its 3-year median value for Gross Profit was $636.9 million (2023), whereas its average is $671.2 million.
  • Data for Halozyme Therapeutics' Gross Profit shows a peak YoY soared of 61.40% (in 2021) over the last 5 years.
  • Yearly analysis of 5 years shows Halozyme Therapeutics' Gross Profit stood at $224.2 million in 2020, then spiked by 61.40% to $361.9 million in 2021, then soared by 43.91% to $520.8 million in 2022, then grew by 22.29% to $636.9 million in 2023, then skyrocketed by 34.39% to $855.9 million in 2024.